250 related articles for article (PubMed ID: 7872342)
21. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease.
Mark PB; Stewart GA; Gansevoort RT; Petrie CJ; McDonagh TA; Dargie HJ; Rodger RS; Jardine AG
Nephrol Dial Transplant; 2006 Feb; 21(2):402-10. PubMed ID: 16221702
[TBL] [Abstract][Full Text] [Related]
22. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension.
Conen D; Zeller A; Pfisterer M; Martina B
Am J Cardiol; 2006 Jan; 97(2):249-52. PubMed ID: 16442372
[TBL] [Abstract][Full Text] [Related]
24. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
[TBL] [Abstract][Full Text] [Related]
25. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
Ogawa S; Takeuchi K; Mori T; Nako K; Ito S
Clin Exp Pharmacol Physiol; 2006; 33(5-6):477-9. PubMed ID: 16700881
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients.
Wang AY; Lam CW; Wang M; Chan IH; Lui SF; Zhang Y; Sanderson JE
Nephrol Dial Transplant; 2009 Jun; 24(6):1962-9. PubMed ID: 19237403
[TBL] [Abstract][Full Text] [Related]
27. Atrial and brain natriuretic peptide and endothelin-1 concentration in patients with idiopathic arterial hypertension: the dependence on the selected morphological parameters.
Irzmański R; Banach M; Piechota M; Kowalski J; Barylski M; Cierniewski C; Pawlicki L
Clin Exp Hypertens; 2007 Apr; 29(3):149-64. PubMed ID: 17497342
[TBL] [Abstract][Full Text] [Related]
28. [Atrial natriuretic peptide, left ventricular mass and renin-angiotensin-aldosterone system in essential arterial hypertension of a mild or moderate degree].
Gambini G; Talamonti D; Valori C
G Ital Cardiol; 1992 Dec; 22(12):1397-403. PubMed ID: 1294423
[TBL] [Abstract][Full Text] [Related]
29. Plasma brain natriuretic peptide during ergometric exercise in hypertensive patients with left ventricular hypertrophy.
Kohno M; Yasunari K; Yokokawa K; Horio T; Kano H; Minami M; Ikeda M; Yoshikawa J
Metabolism; 1996 Nov; 45(11):1326-9. PubMed ID: 8931634
[TBL] [Abstract][Full Text] [Related]
30. N-terminal pro-atrial natriuretic peptide reflects cardiac remodelling in stage 1 hypertension.
Partanen N; Husso M; Vuolteenaho O; Sipola P; Ruskoaho H; Peuhkurinen K; Magga J
J Hum Hypertens; 2011 Dec; 25(12):746-51. PubMed ID: 21248782
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic potential of cardiac natriuretic peptides in dialysis patients.
Mallamaci F; Zoccali C; Tripepi G; Benedetto FA; Parlongo S; Cataliotti A; Cutrupi S; Giacone G; Bellanuova I; Stancanelli B; Malatino LS;
Kidney Int; 2001 Apr; 59(4):1559-66. PubMed ID: 11260421
[TBL] [Abstract][Full Text] [Related]
32. [Regression of hypertensive heart hypertrophy caused by chronic angiotensin-converting enzyme inhibition].
Motz W; Strauer BE
Z Kardiol; 1988 Jan; 77(1):53-60. PubMed ID: 2834885
[TBL] [Abstract][Full Text] [Related]
33. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors.
Kohno M; Yokokawa K; Minami M; Kano H; Yasunari K; Hanehira T; Yoshikawa J
Am J Med; 1999 May; 106(5):544-9. PubMed ID: 10335726
[TBL] [Abstract][Full Text] [Related]
34. [Usefulness of BNP measurement for stratifying cardiovascular risk in hypertensive patients].
Waeber B; Feihl F
Rev Med Suisse; 2011 Sep; 7(308):1748-50. PubMed ID: 21954815
[TBL] [Abstract][Full Text] [Related]
35. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension.
Muscholl MW; Schunkert H; Muders F; Elsner D; Kuch B; Hense HW; Riegger GA
Am Heart J; 1998 Jan; 135(1):58-66. PubMed ID: 9453522
[TBL] [Abstract][Full Text] [Related]
36. Concentration of natriuretic peptides in patients suffering from idiopathic arterial hypertension and left ventricular diastolic dysfunction confirmed by echocardiography.
Irzmański R; Pawlicki L; Charłusz M; Kowalski J
Clin Exp Hypertens; 2012; 34(7):530-40. PubMed ID: 22783987
[TBL] [Abstract][Full Text] [Related]
37. Reduction in left ventricular mass in patients with systemic hypertension treated with enalapril, lisinopril, or fosenopril.
Oren S; Grossman E; Frohlich ED
Am J Cardiol; 1996 Jan; 77(1):93-6. PubMed ID: 8540468
[TBL] [Abstract][Full Text] [Related]
38. Correlation of left ventricular hypertrophy and its regression by lisinopril with salt-induced hypertension.
Snedden W; Fernandez PG; Fernandez D; Vasdev S; Rabin EZ
Can J Cardiol; 1988; 4(5):237-42. PubMed ID: 2842021
[TBL] [Abstract][Full Text] [Related]
39. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy.
Yamamoto K; Burnett JC; Jougasaki M; Nishimura RA; Bailey KR; Saito Y; Nakao K; Redfield MM
Hypertension; 1996 Dec; 28(6):988-94. PubMed ID: 8952587
[TBL] [Abstract][Full Text] [Related]
40. Atrial natriuretic peptide gene promoter polymorphism is associated with left ventricular hypertrophy in hypertension.
Xue H; Wang S; Wang H; Sun K; Song X; Zhang W; Fu C; Han Y; Hui R
Clin Sci (Lond); 2008 Jan; 114(2):131-7. PubMed ID: 17672826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
